Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Vital Farms Inc (VITL) Price & Performance

BioNano Genomics IncTrade
Vital Farms IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Vital Farms Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Vital Farms Inc trades at $13.81 (market cap $561.10M). The key difference: Vital Farms Inc is far larger — about 42.5× BioNano Genomics Inc's market cap, and Vital Farms Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

BNGOVITL
Market Cap
$13.20M$561.10M
Sector
HealthConsumer Staples
52-Week High
$4.92$52.41
52-Week Low
$1.09$8.28
Enterprise Value
$15.81M$563.90M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Vital Farms Inc

Vital Farms (VITL) trades at $12.78, down 1.31% on the day, with a bullish technical signal from moving averages and strong fundamental metrics including a 15.44% ROE and attractive valuation ratios (P/E 12.59, P/S 0.76). Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while revenue grew to $759M in 2025. The stock faces headwinds from multiple class action lawsuits filed in May 2026, creating investor uncertainty despite analyst consensus favoring a buy rating.

The outlook remains cautiously optimistic with a $13.50 consensus price target offering 5.6% upside potential. Key opportunities include sustained profitability and market positioning in natural foods, while risks center on legal challenges and projected earnings volatility. Institutional sentiment leans bullish with no sell ratings, but negative cash flow trends require monitoring.

Returns comparison

Trailing returns across standard periods

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Vital Farms Inc

Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.

Read more on VITL